All In Biotech

Drug Trial Radar · NCT04810078

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 681 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

681

Actual

Start

May 21, 2021

Primary completion

Jul 29, 2025

Study completion May 10, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's substudy is to evaluate drug level biocomparability of subcutaneous nivolumab manufactured using two different manufacturing processes.

Conditions

  • Clear Cell Renal Cell Carcinoma

Interventions

  • Nivolumab and rHuPH20Biological

    Specified dose on specified days

  • NivolumabBiological

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original ScaleTime frame: Pre-dose (Day 1 to Day 28)
  2. Adjusted Geometric Mean of Nivolumab Trough Serum Concentration at Steady State (Cminss) on Original ScaleTime frame: Pre-dose (Day 1 to Day 28)

Locations

89 sites in 17 countries. Site status is shown where the registry gives one.

  • Local Institution

    Chicago, Illinois

  • Local Institution - 0025

    Buffalo, New York

  • Local Institution - 0088

    West Reading, Pennsylvania

  • Local Institution - 0038

    Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0095

    Capital Federal, Buenos Aires, Argentina

  • Local Institution - 0058

    Mar del Plata, Buenos Aires, Argentina

  • Local Institution - 0037

    Pergamino, Buenos Aires, Argentina

  • Local Institution - 0079

    Parana, Córdoba Province, Argentina

  • Local Institution - 0030

    Río Cuarto, Córdoba Province, Argentina

  • Local Institution - 0066

    Viedma, Río Negro Province, Argentina

  • Local Institution - 0056

    San Juan, San Juan Province, Argentina

  • Local Institution - 0064

    Curitiba, Paraná, Brazil

  • Local Institution - 0090

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Local Institution - 0107

    Ijuí, Rio Grande do Sul, Brazil

  • Local Institution - 0039

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution - 0071

    Barretos, São Paulo, Brazil

  • Local Institution - 0070

    São José do Rio Preto, São Paulo, Brazil

  • Local Institution - 0081

    São Paulo, São Paulo, Brazil

  • Local Institution - 0096

    São Paulo, São Paulo, Brazil

  • Local Institution - 0084

    Temuco, Araucania, Chile

  • Local Institution - 0005

    Santiago, Santiago Metropolitan, Chile

  • Local Institution - 0104

    Santiago, Santiago Metropolitan, Chile

  • Local Institution - 0076

    Santiago, Santiago Metropolitan, Chile

  • Local Institution - 0077

    Viña del Mar, Valparaiso, Chile

  • Local Institution - 0063

    Brno, Czechia

  • Local Institution - 0036

    Hradec Králové, Czechia

  • Local Institution - 0020

    Olomouc, Czechia

  • Local Institution - 0099

    Ostrava, Czechia

  • Local Institution - 0010

    Prague, Czechia

  • Local Institution - 0106

    Praha 8 Liben, Czechia

  • Local Institution - 0017

    Tampere, Finland

  • Local Institution

    Nice, France

  • Local Institution - 0051

    Suresnes, France

  • Local Institution - 0068

    Villejuif, France

  • Local Institution - 0060

    Tallaght, Dublin, Ireland

  • Local Institution - 0033

    Cremona, Italy

  • Local Institution - 0008

    Florence, Italy

  • Local Institution - 0027

    Meldola, Italy

  • Local Institution - 0018

    Milan, Italy

  • Local Institution

    Milan, Italy

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.